AstraZeneca (AZN) and Alexion (ALXN) $39bn merger information including expected completion date, offer price and contact details are displayed in the acquisition details table below. An invaluable buyout factsheet for traders and investors looking to trade the merger arbitrage spread.
This deal was successfully consummated on July 21, 2021
| Merger Details | Value |
|---|---|
| Acquisition Target Stock Name | Alexion |
| Acquisition Target Stock Ticker | ALXN |
| Acquirer Name and Ticker | AstraZeneca (AZN) |
| Announcement Date | December 12, 2020 |
| Merger Status | FRIENDLY MERGER |
| Expected Completion Date | Q3, 2021 |
| Deal Value | $39bn |
| Offer Value at Announcement | $175.29 |
| Payment Method | Stock & Cash Deal |
| Stock Ratio | 2.1243 AZN ADR's for each ALXN share |
| Cash Component | $60 |
| Initial Announcement | Press Release |
| AstraZeneca Investor Relations | US general enquiries +1 301 398 3251 |
| Alexion Investor Relations | investorrelations@alexion.com |
| Actual Completion Date | July 21, 2021 |
AstraZeneca (AZN) & Alexion (ALXN) Merger
Receive FREE instant access to constantly updated ALXN news related to the current merger. Simply register by entering your email address to receive weekly publication updates. For more proprietary Merger Arbitrage Limited content and analysis on this buyout, click either AstraZeneca (AZN) or Alexion (ALXN). Proprietary commentary can also be accessed by simply entering a ticker symbol into the search box such as “AZN” or “ALXN“, or clicking on a stock ticker in the tag cloud at the foot of this article.
Traders and shareholders can review similar merger details on current takeover stocks by first selecting “DEALS” from the main menu above, then “Current Cash Deals” or “Current Stock Deals“. For previous acquisitions, select either “Closed Deals” or “Failed Deals“. Additionally, check out our customized M&A PR Newswire or Business Wire press release news feeds exclusively for Merger Arbitrage Limited.
AstraZeneca (NASDAQ: AZN) & Alexion (NASDAQ: ALXN) Merger - Acquisition News and Events
The major acquisition news updates & events of AstraZeneca (AZN) & Alexion (ALXN) by are listed below. A comprehensive data source for
- Traders looking to familiarize themselves with the AstraZeneca (AZN) merger with Alexion (ALXN) and trade the merger arbitrage spread
- Existing shareholders and investors wishing to stay abreast of the latest deal developments
Following the acquisition news section, there are in-depth company profiles.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases.
The company’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Alexion Company Profile
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.
In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity.
Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Finding this information useful? Here's what you can do to help...
- Share this page using the toolbar links at the left of your screen or at the bottom for mobile users on your preferred social network
- Sina Weibo
- Twitter etc.
- Follow us on twitter @MergeArbLimited.
- Become friends with us on Facebook
- Register for news alerts and merger arbitrage deal analysis postings via email using the sign up form.
- In addition to these, an RSS feed is also available at the bottom right of the page.
- Contact us using the details given on the Contact Us page.
- Donate using the paypal widget in the sidebar. It’s gladly appreciated and we need the coffee! See the Paypal section for additional incentives
- Share this page using the toolbar links at the left of your screen or at the bottom for mobile users on your preferred social network
Thanks for reading!
